YOLFTbeta
Oneness Biotech Co Ltd

Oneness Biotech Co Ltd

4743 · TWO · Healthcare / Biotechnology

50.20TWD+4.55 (+9.97%)

Price History

Full chart

Market Stats

Previous Close45.65
Open46.05
Day Range46.05 – 50.20
52-Week Range40.80 – 76.70
Volume4.69M
Market Cap22.61B
P/E (TTM)362.69
Forward P/E0.00
EPS0.13
Dividend Yield0.00%
Beta0.75
50-Day Avg45.73
200-Day Avg52.96

About

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Shuling Cheng Ph.D.
  • Employees0
  • HeadquartersNo. 66, Zhonzheng W. Rd., Taipei, Taiwan, 100, Taiwan
  • Websitehttps://www.onenessbio.com

Leadership

  • Dr. Shuling Cheng Ph.D.President
  • Mr. Nien-Yi ChenDeputy General Manager of Antibody New Drug Division;
  • Mr. Tzu-Chun YangAssociate General Manager of Information Technology Department
  • Mr. Yung-Chi ChengDeputy General Manager of Business Department
  • Ting-Fang ChenFinancial Officer & Acting Spokesperson
  • Ai-Chia YuAccounting Officer
  • Dr. Jui-Ching Chen Ph.D.Director of New Drug Development Department
  • Mr. Kung-Ming LuDirector of Operation Center

Financials

Income Statement

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.63M59.09M3.71M8.60M4.61M5.48M7.84M5.70M2.59M18.86M13.47M41.60M65.77M1.07B86.78M117.93M129.12M
Growth (%)-+3523.11%-93.71%+131.41%-46.39%+18.88%+43.11%-27.27%-54.64%+628.88%-28.54%+208.76%+58.07%+1520.24%-91.86%+35.89%+9.49%
Cost of Revenue435.00K26.75M3.01M5.80M2.77M2.58M4.86M2.85M1.22M10.21M17.00M10.89M20.72M221.16M468.47M54.89M89.25M
Gross Profit1.20M32.34M703.00K2.80M1.84M2.90M2.98M2.85M1.36M8.65M-3.53M30.72M45.04M844.39M-381.69M63.03M39.88M
Gross Margin73.33%54.73%18.92%32.56%39.94%52.89%38.07%50.01%52.76%45.86%-26.17%73.83%68.49%79.24%-439.82%53.45%30.88%
Operating Expense28.50M57.12M78.10M83.70M124.84M121.08M100.19M116.00M140.46M140.83M316.48M275.48M436.11M388.17M714.93M1.15B838.96M
Operating Income-27.31M-24.77M-77.40M-80.90M-123.00M-118.18M-97.21M-113.15M-139.09M-132.19M-320.00M-244.76M-391.06M456.22M-1.10B-1.09B-799.08M
Operating Margin-1674.19%-41.92%-2083.42%-941.03%-2668.58%-2156.93%-1239.74%-1984.10%-5376.61%-701.03%-2374.80%-588.30%-594.64%42.82%-1263.64%-920.42%-618.85%
EBITDA-47.06M-38.59M-68.14M-178.63M-98.05M-111.76M-86.29M-9.74M-150.68M-233.29M-253.86M-52.15M-193.72M950.86M-648.12M-685.71M-712.76M
EBITDA Margin-2885.65%-65.30%-1834.21%-2077.79%-2127.42%-2039.75%-1100.52%-170.87%-5824.55%-1237.22%-1883.94%-125.34%-294.56%89.24%-746.83%-581.47%-552.00%
Net Income6.28M953.00K13.96M-27.39M276.25M199.73M-93.02M-14.26M-155.45M-235.44M-328.46M-251.68M-412.82M359.98M-1.31B-1.17B-1.04B
Net Income Margin385.04%1.61%375.67%-318.60%5993.77%3645.30%-1186.29%-249.99%-6008.74%-1248.60%-2437.57%-604.92%-627.72%33.78%-1512.82%-988.03%-809.13%
R&D19.65M40.41M53.70M49.06M75.50M60.94M53.59M62.68M65.43M94.44M238.64M589.28M805.96M919.02M538.29M924.89M605.87M
R&D as % of Total Revenue1204.90%68.38%1445.41%570.62%1637.99%1112.21%683.48%1099.00%2529.26%500.83%1770.97%1416.37%1225.52%86.25%620.28%784.30%469.22%
Interest Expense------3.00K8.00K5.00K6.00K6.26M5.18M4.90M4.59M5.61M9.61M8.90M
Interest Expense % of Total Revenue------0.04%0.14%0.19%0.03%46.43%12.45%7.45%0.43%6.46%8.15%6.89%

Balance Sheet

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.11B1.11B1.39B1.43B2.09B2.01B2.81B2.56B2.52B2.34B6.98B15.38B15.73B15.58B15.36B13.66B11.73B
Total Liabilities6.75M18.64M20.09M21.41M123.82M79.87M41.72M31.41M26.46M169.64M520.96M1.62B1.64B700.38M866.43M859.65M1.26B
Total Equity1.11B1.09B1.37B1.40B1.97B1.93B2.77B2.52B2.35B2.03B6.33B13.63B14.02B14.62B14.05B12.30B10.33B
Cash678.43M781.41M334.55M228.05M77.98M41.79M694.94M194.33M244.13M150.67M166.56M217.64M332.96M5.66B812.83M1.05B1.66B
Total Debt74.00K3.99M4.77M8.43M9.02M8.50M55.00K20.00K25.00K81.00K328.61M303.09M283.82M263.45M432.20M--
Net Debt-678.35M-777.42M-329.78M-219.62M-68.96M-33.29M-694.88M-194.31M-244.11M-150.59M162.05M85.45M-49.13M-5.39B-380.63M--

Cash Flow

Currency: TWD2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-102.30M153.25M-29.27M24.15M-89.26M-150.98M-142.34M-108.54M-165.27M-5.12M-213.25M158.14M-288.89M-881.00M-395.13M-345.58M-460.24M
Investing Cash Flow-------197.50M-401.71M59.09M-88.34M243.49M-5.70B59.54M5.74B---
Financing Cash Flow527.78M-12.00M224.09M-11.63M14.82M-15.18M993.00M9.63M155.99M56.00K-14.32M5.60B344.67M451.87M386.47M--
Capital Expenditure4.21M15.28M1.75M9.30M84.76M4.63M61.84M152.04M313.17M167.25M47.27M153.27M100.29M89.19M90.92M53.28M26.50M
Free Cash Flow-106.51M137.97M-31.01M14.85M-174.02M-155.61M-204.19M-260.58M-478.44M-172.37M-260.53M4.87M-389.19M-970.19M-486.05M-398.86M-486.74M
Dividends Paid11.02M12.00M-11.63M-25.76M17.78M-------39.09M--
FCF to OCF104.11%90.03%105.97%61.50%194.96%103.07%143.45%240.08%289.49%3364.61%122.17%3.08%134.72%110.12%123.01%115.42%105.76%
Dividend Paid to FCF-10.35%8.70%-78.33%--16.55%-8.71%--------8.04%--

Earnings

Report DateMar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Jun 1, 2011Aug 31, 2011Oct 28, 2011Feb 29, 2012May 2, 2012Aug 29, 2012Oct 31, 2012Feb 23, 2013May 29, 2013Aug 28, 2013Nov 27, 2013Feb 26, 2014May 28, 2014Sep 3, 2014Dec 3, 2014Feb 25, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 31, 2016Nov 9, 2016Mar 1, 2017May 31, 2017Aug 30, 2017Nov 8, 2017Feb 28, 2018May 30, 2018Aug 29, 2018Nov 7, 2018Feb 27, 2019May 29, 2019Aug 28, 2019Nov 6, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Nov 11, 2020Feb 27, 2021May 6, 2021Aug 6, 2021Nov 5, 2021Mar 16, 2022May 11, 2022Aug 11, 2022Nov 9, 2022Feb 24, 2023May 15, 2023Aug 11, 2023Nov 9, 2023Mar 11, 2024Mar 31, 2024Aug 11, 2024Nov 10, 2024Mar 5, 2025
EPS Estimate-------0.08--0.08--0.12-0.11----------------------------------------2.14-0.08-0.65-0.70-0.24-0.30-0.34-0.38-0.56
EPS Actual0.04-0.04-0.040.08-0.100.16-0.030.040.21-0.19-0.210.050.100.610.90-0.22-0.100.000.910.20-0.13-0.10-0.08-0.13-0.15-0.110.37-0.17-0.18-0.17-0.15-0.20-0.25-0.08-0.50-0.22-0.14-0.29-0.19-0.43-0.471.150.05-1.600.31-1.24-0.460.340.990.870.71-1.66-0.57-0.70-0.50-1.02-0.19-0.36-1.06-0.82
Surprise------62.50%-362.50%--75.00%145.45%---------------------------------------22.43%-612.50%-7.69%28.57%-325.00%37.50%-5.88%-178.95%-46.43%
Timing------After-hours-After-hours-After-hoursAfter-hours-------------------------------Pre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-After-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap22.61B
Enterprise Value16.57B
Trailing P/E362.69
Forward P/E0.00
Price / Sales147.02
Price / Book2.11
EPS0.13
Book Value21.37
Revenue (TTM)153.78M
Gross Profit (TTM)56.74M
EBITDA-507.98M
Profit Margin39.55%
Operating Margin-514.87%
Return on Equity0.62%
Return on Assets-4.27%
Shares Outstanding479.50M
Shares Float326.78M
Beta0.75
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.10Jun 16, 2023
20151×
0.09Aug 24, 2015
20141×
0.16Aug 25, 2014
20121×
0.07Sep 6, 2012
20101×
0.07May 17, 2010

Stock Splits

  • Jun 16, 20233312:2911
  • Aug 24, 2015109:100
  • Feb 10, 20153343:3239
  • Aug 25, 201459:50
  • Sep 6, 201298163:89239
  • Oct 13, 20111885:1804
  • Dec 7, 20091006:759